Table 4

Triple combination with/without EGFR inhibitors

			n	RR			PFS			OS
				(%)	p Value	Median	HR	p Value	Median	HR	p Value
	ITT population
PACCE	5-FU/FA/Ox–Bev		410	48	NS	11.4	1.27	NS	24.5	1.43
	5-FU/FA/Ox–Bev–Pan		413	46	NS	10.0	1.27	NS	19.4	1.43
	5-FU/FA/Iri–Bev		115	40	NS	11.7	1.19	NS	20.5	1.42	NS
	5-FU/FA/Iri–Bev–Pan		115	43	NS	10.1	1.19	NS	20.7	1.42	NS
CAIRO	XELOX–Bev		368	50	NS	10.7	1.22	0.01	20.3	1.15	0.16
CAIRO	XELOX–Bev–Cet		368	53		9.4			19.4
	K-ras population
PACCE 82% ITT of population	5-FU/FA/Ox–Bev	WT	203	56	NA	11.5	1.36	NA	24.5	1.89	NS
	5-FU/FA/Ox–Bev–Pan	WT	201	50	NA	9.8	1.36	NA	20.7	1.89	NS
	5-FU/FA/Iri–Bev	WT	58	48	NA	12.5	1.50	NA	NA	NA	NA
	5-FU/FA/Iri–Bev–Pan	WT	57	54		10.0	1.50	NA	19.8	NA	NA
	5-FU/FA/Ox–Bev	mut	125	44	NA	11.0	1.25	NS	19.3	1.02	NS
	5-FU/FA/Ox–Bev–Pan	mut	135	47		10.4	1.25	NS	19.3	1.02	NS
	5-FU/FA/Iri–Bev	mut	39	38	NA	11.9	1.9	NA	20.5	2.14	NS
	5-FU/FA/Iri–Bev–Pan	mut	47	30		9.3	1.9	NA	17.9	2.14	NS

Bev, bevacizumab; Cet, cetuximab; EGFR, epidermal growth factor receptor; FA, folinic acid; 5-FU, 5-fluorouracil; Iri, irinotecan; ITT, intention to treat; mut, mutated; NA, not available; NS, non-significant; OS, overall survival; Ox, oxaliplatin; Pan, panitumumab; PFS, progression-free survival; WT, wild type.